durvalumab,datopotamab,Paclitaxel,Capivasertib,Oleclumab
daiichi sankyo,astrazeneca,otuska
the combination of the trop2-directed adc datopotamab deruxtecan &amp; durvalumab had early activity when used as first-line treatment in patients with locally advanced or metastatic triple-negative breast cancer. #esmobreast22 #bcsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.